
Veru (VERU) Stock Forecast & Price Target
Veru (VERU) Analyst Ratings
Bulls say
Veru Inc. has shown strong potential in its drug development programs, highlighted by the successful initial topline results from the Phase 2b QUALITY trial, which could align with FDA's expectations for upcoming Phase 3 design discussions. The company's focus on metabolic diseases and solid management experience enhances its credibility, suggesting a strategic shift that could provide growth opportunities, despite certain risks associated with its flagship product, Enobosarm. Furthermore, the forecast of profitability by 2029, coupled with its focused niche pipeline, indicates a positive long-term outlook for Veru's financial performance.
Bears say
Veru Inc faces significant risks that may adversely affect its future financial performance, primarily stemming from volatility in industry fundamentals related to customer demand and pricing for its biopharmaceutical products. The presence of major competitors and potential shifts in market share or new product developments could negatively influence investor sentiment towards the company. Additionally, any unforeseen developments concerning the company's management, financial condition, or accounting practices could result in a detrimental effect on its valuation, contributing to an overall negative outlook.
This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.
Veru (VERU) Analyst Forecast & Price Prediction
Start investing in Veru (VERU)
Order type
Buy in
Order amount
Est. shares
0 shares